Arcadia Total Current Assets vs Total Current Liabilities Analysis

RKDA Stock

USD 2.74 0.15 5.79%

Arcadia Biosciences financial indicator trend analysis is way more than just evaluating Arcadia Biosciences prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Arcadia Biosciences is a good investment. Please check the relationship between Arcadia Biosciences Total Current Assets and its Total Current Liabilities accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Arcadia Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.

For information on how to trade Arcadia Stock refer to our How to Trade Arcadia Stock guide.

Total Current Assets vs Total Current Liabilities

Total Current Assets vs Total Current Liabilities Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Arcadia Biosciences Total Current Assets account and Total Current Liabilities. At this time, the significance of the direction appears to have weak contrarian relationship.

The correlation between Arcadia Biosciences' Total Current Assets and Total Current Liabilities is -0.2. Overlapping area represents the amount of variation of Total Current Assets that can explain the historical movement of Total Current Liabilities in the same time period over historical financial statements of Arcadia Biosciences, assuming nothing else is changed. The correlation between historical values of Arcadia Biosciences' Total Current Assets and Total Current Liabilities is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Current Assets of Arcadia Biosciences are associated (or correlated) with its Total Current Liabilities. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Current Liabilities has no effect on the direction of Total Current Assets i.e., Arcadia Biosciences' Total Current Assets and Total Current Liabilities go up and down completely randomly.

Correlation Coefficient

-0.2

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Total Current Assets

The total value of all assets that are expected to be converted into cash within one year or during the normal operating cycle.

Total Current Liabilities

Total Current Liabilities is an item on Arcadia Biosciences balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Arcadia Biosciences are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Most indicators from Arcadia Biosciences' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Arcadia Biosciences current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Arcadia Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.

For information on how to trade Arcadia Stock refer to our How to Trade Arcadia Stock guide.At present, Arcadia Biosciences' Tax Provision is projected to decrease significantly based on the last few years of reporting. The current year's Issuance Of Capital Stock is expected to grow to about 11.4 M, whereas Selling General Administrative is forecasted to decline to about 14.7 M.

	2021	2022	2023	2024 (projected)
Total Operating Expenses	26.8M	19.6M	16.0M	21.7M
Cost Of Revenue	8.7M	9.8M	3.3M	3.1M

Total Operating Expenses Cost Of Revenue

Arcadia Biosciences fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Other Liab	Other Assets	Long Term Debt
Total Assets		0.56	-0.29	-0.15	0.88	0.29	-0.18	0.03	-0.28	0.51	0.51	0.72	0.11	0.93	-0.19	0.03	0.5	0.21	0.52	0.42	0.43	0.26	0.97	-0.14	0.04	0.49
Short Long Term Debt Total	0.56		0.01	0.17	0.18	-0.19	0.56	0.7	0.52	0.02	0.02	0.56	0.13	0.59	-0.02	-0.51	0.9	-0.41	-0.23	-0.38	0.9	-0.3	0.49	-0.25	0.37	0.94
Other Current Liab	-0.29	0.01		0.75	-0.51	0.23	0.18	0.25	0.22	-0.68	-0.29	-0.2	0.31	-0.26	0.35	-0.27	0.13	0.01	-0.25	-0.3	0.32	0.16	-0.28	0.46	0.43	-0.15
Total Current Liabilities	-0.15	0.17	0.75		-0.34	0.17	0.1	0.07	0.16	-0.28	0.1	0.05	0.6	-0.18	0.37	-0.16	0.05	0.04	-0.17	-0.2	0.31	0.12	-0.2	0.08	0.56	-0.08
Total Stockholder Equity	0.88	0.18	-0.51	-0.34		0.4	-0.47	-0.36	-0.57	0.64	0.67	0.57	0.08	0.81	-0.18	0.27	0.08	0.45	0.76	0.73	-0.01	0.42	0.87	-0.27	-0.13	0.13
Property Plant And Equipment Net	0.29	-0.19	0.23	0.17	0.4		-0.38	-0.37	-0.36	0.01	0.37	0.39	0.47	0.15	0.37	0.1	-0.15	0.86	0.77	0.45	-0.1	0.96	0.22	0.0	0.44	-0.35
Current Deferred Revenue	-0.18	0.56	0.18	0.1	-0.47	-0.38		0.58	0.96	-0.33	-0.26	0.11	-0.12	-0.1	0.31	-0.81	0.6	-0.6	-0.65	-0.89	0.6	-0.55	-0.25	-0.11	0.46	0.57
Net Debt	0.03	0.7	0.25	0.07	-0.36	-0.37	0.58		0.58	-0.44	-0.69	0.05	-0.01	0.1	-0.18	-0.38	0.72	-0.61	-0.55	-0.61	0.7	-0.39	0.02	0.03	0.17	0.73
Retained Earnings	-0.28	0.52	0.22	0.16	-0.57	-0.36	0.96	0.58		-0.33	-0.29	0.06	-0.1	-0.18	0.29	-0.83	0.59	-0.59	-0.69	-0.93	0.61	-0.53	-0.35	-0.03	0.5	0.54
Accounts Payable	0.51	0.02	-0.68	-0.28	0.64	0.01	-0.33	-0.44	-0.33		0.59	0.37	-0.14	0.48	-0.48	0.13	-0.04	0.06	0.34	0.44	-0.11	0.02	0.49	-0.1	-0.26	-0.02
Cash	0.51	0.02	-0.29	0.1	0.67	0.37	-0.26	-0.69	-0.29	0.59		0.5	0.18	0.44	0.28	0.05	-0.1	0.5	0.58	0.47	-0.07	0.3	0.46	-0.28	0.17	-0.08
Non Current Assets Total	0.72	0.56	-0.2	0.05	0.57	0.39	0.11	0.05	0.06	0.37	0.5		0.41	0.51	0.2	-0.1	0.46	0.23	0.29	0.08	0.45	0.35	0.52	-0.26	0.43	0.46
Non Currrent Assets Other	0.11	0.13	0.31	0.6	0.08	0.47	-0.12	-0.01	-0.1	-0.14	0.18	0.41		-0.07	0.42	0.21	-0.11	0.36	0.25	0.09	0.05	0.54	-0.01	-0.41	0.7	-0.07
Cash And Short Term Investments	0.93	0.59	-0.26	-0.18	0.81	0.15	-0.1	0.1	-0.18	0.48	0.44	0.51	-0.07		-0.32	-0.14	0.58	0.06	0.42	0.4	0.5	0.08	0.96	-0.08	-0.05	0.54
Net Receivables	-0.19	-0.02	0.35	0.37	-0.18	0.37	0.31	-0.18	0.29	-0.48	0.28	0.2	0.42	-0.32		-0.22	-0.13	0.36	0.1	-0.27	-0.02	0.26	-0.31	-0.39	0.66	-0.08
Common Stock Shares Outstanding	0.03	-0.51	-0.27	-0.16	0.27	0.1	-0.81	-0.38	-0.83	0.13	0.05	-0.1	0.21	-0.14	-0.22		-0.62	0.44	0.42	0.64	-0.65	0.36	0.06	-0.07	-0.49	-0.42
Non Current Liabilities Total	0.5	0.9	0.13	0.05	0.08	-0.15	0.6	0.72	0.59	-0.04	-0.1	0.46	-0.11	0.58	-0.13	-0.62		-0.41	-0.29	-0.44	0.96	-0.29	0.46	0.13	0.27	0.89
Inventory	0.21	-0.41	0.01	0.04	0.45	0.86	-0.6	-0.61	-0.59	0.06	0.5	0.23	0.36	0.06	0.36	0.44	-0.41		0.88	0.63	-0.38	0.89	0.17	-0.09	0.16	-0.47
Other Current Assets	0.52	-0.23	-0.25	-0.17	0.76	0.77	-0.65	-0.55	-0.69	0.34	0.58	0.29	0.25	0.42	0.1	0.42	-0.29	0.88		0.79	-0.32	0.79	0.53	-0.24	0.02	-0.29
Other Stockholder Equity	0.42	-0.38	-0.3	-0.2	0.73	0.45	-0.89	-0.61	-0.93	0.44	0.47	0.08	0.09	0.4	-0.27	0.64	-0.44	0.63	0.79		-0.47	0.58	0.49	-0.05	-0.4	-0.43
Total Liab	0.43	0.9	0.32	0.31	-0.01	-0.1	0.6	0.7	0.61	-0.11	-0.07	0.45	0.05	0.5	-0.02	-0.65	0.96	-0.38	-0.32	-0.47		-0.24	0.38	0.14	0.41	0.82
Property Plant And Equipment Gross	0.26	-0.3	0.16	0.12	0.42	0.96	-0.55	-0.39	-0.53	0.02	0.3	0.35	0.54	0.08	0.26	0.36	-0.29	0.89	0.79	0.58	-0.24		0.19	-0.01	0.31	-0.43
Total Current Assets	0.97	0.49	-0.28	-0.2	0.87	0.22	-0.25	0.02	-0.35	0.49	0.46	0.52	-0.01	0.96	-0.31	0.06	0.46	0.17	0.53	0.49	0.38	0.19		-0.08	-0.1	0.44
Other Liab	-0.14	-0.25	0.46	0.08	-0.27	0.0	-0.11	0.03	-0.03	-0.1	-0.28	-0.26	-0.41	-0.08	-0.39	-0.07	0.13	-0.09	-0.24	-0.05	0.14	-0.01	-0.08		-0.31	-0.23
Other Assets	0.04	0.37	0.43	0.56	-0.13	0.44	0.46	0.17	0.5	-0.26	0.17	0.43	0.7	-0.05	0.66	-0.49	0.27	0.16	0.02	-0.4	0.41	0.31	-0.1	-0.31		0.17
Long Term Debt	0.49	0.94	-0.15	-0.08	0.13	-0.35	0.57	0.73	0.54	-0.02	-0.08	0.46	-0.07	0.54	-0.08	-0.42	0.89	-0.47	-0.29	-0.43	0.82	-0.43	0.44	-0.23	0.17

Click cells to compare fundamentals

Arcadia Biosciences Account Relationship Matchups

Arcadia Biosciences fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	32.6M	47.3M	43.9M	28.9M	19.7M	35.9M
Other Current Liab	4.5M	3.0M	1.5M	1.3M	1.1M	1.8M
Total Current Liabilities	5.7M	6.3M	5.0M	4.2M	3.6M	4.1M
Total Stockholder Equity	7.7M	27.7M	31.1M	21.0M	12.8M	14.6M
Property Plant And Equipment Net	3.8M	9.4M	5.4M	2.6M	1.2M	1.1M
Current Deferred Revenue	42K	8K	64K	(572K)	(514.8K)	(489.1K)
Net Debt	(6.2M)	(4.7M)	(25.4M)	(18.6M)	(5.5M)	(5.8M)
Retained Earnings	(207.2M)	(211.8M)	(226.5M)	(257.9M)	(271.8M)	(285.4M)
Accounts Payable	492K	726K	1.4M	905K	801K	970.9K
Cash	8.4M	14.0M	28.7M	20.6M	6.5M	6.2M
Non Current Assets Total	4.1M	15.7M	8.5M	3.5M	4.7M	5.5M
Non Currrent Assets Other	372K	5.5M	2.7M	932K	3.5M	2.5M
Cash And Short Term Investments	25.3M	25.7M	28.7M	20.6M	11.6M	11.1M
Net Receivables	602K	1.4M	1.4M	1.2M	514K	767.9K
Common Stock Shares Outstanding	159.1K	249.0K	532.0K	599.4K	1.2M	1.3M
Liabilities And Stockholders Equity	32.6M	47.3M	43.9M	28.9M	19.7M	35.9M
Non Current Liabilities Total	18.5M	12.5M	7.7M	3.8M	3.4M	3.2M
Inventory	1.8M	3.8M	4.4M	2.6M	2.0M	1.6M
Other Current Assets	712K	1.6M	1.8M	1.2M	858K	914.0K
Other Stockholder Equity	214.8M	239.5M	257.5M	278.8M	284.5M	207.1M
Total Liab	24.2M	18.8M	12.7M	8.0M	7.0M	6.7M
Property Plant And Equipment Gross	3.8M	9.4M	5.4M	2.6M	3.7M	2.7M
Total Current Assets	28.4M	31.7M	35.4M	25.4M	15.0M	28.3M
Accumulated Other Comprehensive Income	(4.8M)	1K	0.0	101K	116.2K	122.0K
Other Liab	8.2M	16.9M	5.0M	5.5M	6.3M	8.1M
Other Assets	372K	5.5M	2.7M	1.0	0.9	0.86
Short Term Debt	635K	2.6M	2.1M	2.0M	1.7M	1.6M
Property Plant Equipment	1.1M	2.2M	9.4M	5.4M	6.2M	3.1M
Net Tangible Assets	12.8M	7.7M	26.9M	30.6M	35.2M	37.0M
Common Stock Total Equity	42K	45K	49K	54K	62.1K	51.0K
Retained Earnings Total Equity	(167.3M)	(178.4M)	(207.2M)	(211.8M)	(190.6M)	(200.2M)
Short Term Investments	9.8M	16.9M	11.6M	0.0	5.1M	4.9M
Capital Surpluse	175.2M	191.1M	214.8M	239.5M	275.4M	213.9M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

When determining whether Arcadia Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Arcadia Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Arcadia Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Arcadia Biosciences Stock:

How To Invest In Arcadia

Details

Is Arcadia Stock a good investment?

Details

What is Arcadia Biosciences' Net Worth?

Details

Largest Agricultural Products & Services Companies

View

Largest Food, Beverage & Tobacco Companies

View

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Arcadia Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.

For information on how to trade Arcadia Stock refer to our How to Trade Arcadia Stock guide.

You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.

Is Agricultural Products & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Arcadia Biosciences. If investors know Arcadia will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Arcadia Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

0.285

Earnings Share

(6.77)

Revenue Per Share

3.802

Quarterly Revenue Growth

(0.04)

Return On Assets

(0.39)

The market value of Arcadia Biosciences is measured differently than its book value, which is the value of Arcadia that is recorded on the company's balance sheet. Investors also form their own opinion of Arcadia Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Arcadia Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Arcadia Biosciences' market value can be influenced by many factors that don't directly affect Arcadia Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Arcadia Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Arcadia Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Arcadia Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Arcadia Total Current Assets vs Total Current Liabilities Analysis

Total Current Assets vs Total Current Liabilities

Total Current Assets vs Total Current Liabilities Correlation Analysis

Correlation Coefficient

Total Current Assets

Total Current Liabilities

Arcadia Biosciences fundamental ratios Correlations

Arcadia Biosciences Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Arcadia Biosciences fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 0.97	Total Assets
Property Plant And Equipment Gross	+ 0.96	Property Plant And Equipment Net
Retained Earnings	+ 0.96	Current Deferred Revenue
Total Current Assets	+ 0.96	Cash And Short Term Investments
Total Liab	+ 0.96	Non Current Liabilities Total
Long Term Debt	+ 0.94	Short Long Term Debt Total

Other Stockholder Equity	- 0.93	Retained Earnings
Other Stockholder Equity	- 0.89	Current Deferred Revenue
Common Stock Shares Outstanding	- 0.83	Retained Earnings
Common Stock Shares Outstanding	- 0.81	Current Deferred Revenue
Other Current Assets	- 0.69	Retained Earnings
Cash	- 0.69	Net Debt